All posts by Ciara Jackson

Aptar’s Nasal Unidose Device Approved by US FDA for First Needl...

Crystal Lake, Illinois, July 25, 2019 – AptarGroup, Inc., a global leader in dispensing and drug delivery solutions, today announced that its Unidose Powder System was recently approved by the U.S. Food and Drug Administration (FDA) for an intranasal, needle-free rescue treatment drug intended to treat severe hypoglycemia in people with diabetes. This marks the first FDA approval of a prescription drug using Aptar’s patented Unidose Powder System and is Aptar’s first combination of a drug delivery device with a protective active packaging container.

This approval again demonstrates Aptar’s expertise in developing patient-friendly drug delivery solutions for breakthrough medicines. Aptar offers a broad portfolio of innovative technologies and wide array of services to meet the highest quality standards of the pharmaceutical industry.

Solution for Nasally Administered Powder Treatments

Aptar’s Unidose Powder System is a single-use, ready-to-use one-step nasal delivery device which can deliver a powder formulation in an emergency situation quickly and easily. During such an event, the patient or caregiver presses a small plunger on the bottom of the device to release the drug in a single powder puff into the nose, where the drug can be quickly absorbed via the nasal mucosa. Aptar’s Unidose Powder System is an alternative to injectable kits that may require assembly, including a multistep, time-consuming process of mixing powder and liquid.

Patented Unidose and Bidose Technology Platforms

Aptar’s Unidose and Bidose platforms are robust, primeless, and easy-to-use systems with 360° functionality and precise nasal drug delivery. They offer biotech and pharmaceutical companies effective and reliable single or two-shot intranasal delivery for a variety of medicines including potential life-saving drugs and treatments of severe conditions. The devices can also integrate wireless connectivity technologies.

Unidose Device Protected by Aptar’s Integrated Active Packaging Container

This is the first approval and customer launch combining the technologies of Aptar Pharma and Aptar CSP Technologies. The novel container, which protects and stores the Unidose Powder System, was developed by Aptar CSP Technologies, the global material science unit of Aptar, providing innovative, highly engineered advanced active packaging solutions that protect sensitive drug products. The container incorporates Aptar’s three phase Activ-Polymer™ technology which ensures extended moisture protection for the shelf-life of the drug, mitigating the impact of changing environmental conditions associated with temperature and relative humidity.

Accelerated Development Support via Aptar Pharma Services

This innovative therapy in the field of diabetes is an example of a Combination Product submission, and benefited from Aptar Pharma’s Services offering, a comprehensive portfolio of stage-specific development packages. Aptar’s dedicated Regulatory Affairs experts and analytical scientists help customers proactively address regulatory needs to accelerate approval.

“We are pleased to announce that Aptar Pharma’s Unidose Powder System has been approved by the FDA for the first intranasally-delivered, needle-free rescue treatment for severe hypoglycemia that provides a more patient-friendly delivery approach. Our active packaging container helps to protect the device and better ensure its quality until the moment of use,” commented Gael Touya, President, Aptar Pharma. “This project marks a nearly 10-year customer collaboration and once again demonstrates Aptar Pharma’s ability to help our customers develop and launch complex treatments with patient-friendly delivery systems worldwide.”

Stephan Tanda, Aptar’s President and CEO added, “This successful approval confirms the value that we are bringing to our customers in the highly competitive pharmaceutical and biotech industries. With decades of experience in the long-term testing and development phases that are required by regulatory agencies, we are building a stronger solutions platform for the future, and this launch is a glimpse of that future. Our lab and analytic service capabilities combined with our unique drug delivery devices and active packaging solutions create tremendous value for our customers and help them secure approval. The ultimate end result is that we help expand access to life-saving treatments with our patient-friendly systems.”

Download the full Press Release.

 

July 25, 2019

Aptar Pharma Unveils PureHale in Latin America during FCE Pharma ...

Aptar Pharma is pleased to be a key exhibitor at this year’s FCE Pharma exhibition, taking place from May 21-23 at the São Paulo Expo, Sao Paulo, Brazil.

Aptar Pharma has been exhibiting at this key industry event for a number of years and is looking forward to once again sharing our latest innovations at this year’s show.

At Booth No. H021, Hall H, visitors are invited to meet with our drug delivery experts, who will be on hand to present Aptar Pharma’s expanding portfolio of drug delivery solutions and technology innovations across nasal, pulmonary, eye care, dermal and injectable routes.

A highlight of our presence at FCE Pharma 2019 will be the unveiling of Aptar Pharma’s PureHale for the first time in Latin America.  PureHale is a portable and ready-to-use nebulizer-like device, designed to deliver natural care to upper airways.

With growing customer interest in the Latin American market for preservative-free formulations, visitors to the Aptar Pharma booth will have the opportunity to find out more about our Ophthalmic Squeeze Dispense (OSD).  With more than 200 market references worldwide, the Aptar Pharma Ophthalmic Squeeze Dispenser is the first and only FDA approved preservative-free dispensing technology, is suitable for a wide range of viscosities, and was recently approved across Europe for Glaucoma prescription treatment.

FCE Pharma is considered the key annual pharmaceutical and cosmetics tradeshow in Latin America, bringing together all the major players in the pharmaceutical industry to share their knowledge and expertise, exchange ideas and showcase the latest trends and innovations. More than 23,000 visitors are expected to attend this year’s event.

Visit Aptar Pharma at FCE Pharma 2019.  We look forward to welcoming you.

May 17, 2019

Aptar Pharma’s Freepod® Nasal Spray Device with GlaxoSmithKlin...

Aptar Pharma, a leading provider of innovative drug delivery systems, has announced that its patented Freepod® nasal spray device with GlaxoSmithKline’s Otrivin® has won a Medical & Pharma category award at the World Packaging Organization (WPO) 2019 WorldStar Packaging Awards ceremony, which took place on May 15, 2019 in Prague.

GlaxoSmithKline’s Otrivin® is well-known globally for providing temporary relief of nasal congestion.  Aptar Pharma’s Freepod®, a multi-dose preservative-free nasal spray pump, with GlaxoSmithKline’s Otrivin® was recognized by the WorldStar Awards jury for its sustainability impact.

Howard Burnett, Aptar Pharma Vice-President Global Account Management, commented, “We congratulate GlaxoSmithKline on this prestigious WorldStar Packaging Award win. At Aptar Pharma, we’re very proud that our patented Freepod® technology has been recognized with GlaxoSmithKline’s Otrivin® as a deserving winner in the Medical & Pharma category of the WorldStar Packaging Award.”

The WorldStar Awards Competition, hosted by the WPO, recognizes the continual advancement and excellence in packaging design and technology, and is considered to be one of the most prestigious international packaging awards events.

Full details found in the Press Release.

 

May 16, 2019

Aptar Pharma to Demonstrate its Expertise in Multi-dose Preservat...

Aptar Pharma, a leading provider of drug delivery systems, services and active packaging solutions worldwide, is pleased to be a key exhibitor at ARVO 2019, taking place on April 28 – May 2 at the Vancouver Convention Center, Vancouver, Canada.

ARVO is an annual international conference, bringing together eye and vision researchers to provide the public, patients and policymakers with insight into how their sight-saving work greatly benefits society.  The theme for ARVO 2019 – ‘From bench to bedside and back’ – will highlight the importance of the full journey that often takes place from research labs to the patient and back to the bench again, in the search for a novel treatment.

Aptar Pharma will exhibit at Booth No. 928, where we will demonstrate our expertise in the field of multi-dose preservative-free packaging for Eye Care to ARVO’s 11,000 expected delegates.

With over 200 references for both prescription medications and consumer products, Aptar Pharma will have a special focus on our Preservative-free multidose Ophthalmic Squeeze Dispenser, which was recently approved for Santen’s prescription treatment for glaucoma in 26 European countries.

Our versatile Ophthalmic Squeeze Dispenser Technology Platform allows for a wide range of configurations and applications, enabling customized solutions for specific ophthalmic formulations. With Aptar Pharma known for creating the first and only FDA-reviewed preservative free dispensing technology, our experts will provide delegates with insight into how we can accelerate customers’ speed-to-market in line with industry standards.

To connect with Aptar Pharma and meet our team of experts, register here for ARVO 2019 today.

 

 

 

April 19, 2019

Aptar Pharma to Exhibit Latest Drug Delivery Innovations at CPhI ...

Aptar Pharma is pleased to be exhibiting at CPhI North America 2019, taking place on April 30–May 2 at McCormick Place in Chicago, Illinois.

At Booth 1721, Aptar Pharma experts will be on hand to present our diverse portfolio of drug delivery systems, services and active packaging solutions, as well as our latest innovations including:

  • Our Bidose nasal drug delivery device, recently approved by the U.S. FDA for a breakthrough treatment of depression
  • Our industry award-winning Aptar Pharma QuickStart™ Injectables – our Ready-to-Use drug development support package designed to accelerate time-to-market for research and development labs
  • Our recently launched PureHale – a portable and ready-to-use device designed to deliver natural care to upper airways

Also, discover Aptar Pharma’s expanded range of connected drug delivery devices, demonstrating our investment in the future of digital medicines, at CPhI North America 2019.  Talk to our experts about our active packaging solutions portfolio from Aptar CSP Technologies, now part of the Aptar family, helping to optimize your drug product’s packaging environment.

Find out how Aptar Pharma is expanding its North America manufacturing to be closer to customers.  Equipped with the latest technologies to meet growing quality requirements for regulated markets, our recently expanded capabilities at our Congers, NY site will continue to deliver solutions to our customers’ drug delivery challenges.

CPhI North America expects to welcome more than 6,500 industry professionals this year.  During this three-day event, leaders from across the pharma supply chain will gather to exchange ideas, build partnerships and shape the future of the field.

To register for this event, please click here.

April 18, 2019

Aptar Pharma’s Global Services Offering Featured in ONdrugDeliv...

Aptar Pharma is featured in the April 2019 edition of ONdrugDelivery magazine, which focuses this month on Pulmonary & Nasal Drug Delivery.

In this in-depth interview, Aptar Pharma’s Guillaume Brouet, Vice-President Analytical, Regulatory and Scientific Affairs, discusses Aptar Pharma’s comprehensive range of services available to customers around device development, the importance of offering services with a patient-centric approach, and Aptar’s proven expertise in regulatory and combination product approvals.

Read the full article here.

April 11, 2019

Aptar Pharma Co-Organizer and Diamond Sponsor of RDD Europe 2019 ...

Aptar Pharma, the leader in respiratory drug delivery systems, is proud to announce its co-organization and diamond sponsorship of the Respiratory Drug Delivery (RDD®) Europe 2019 scientific conference, connecting pulmonary and nasal drug delivery experts from around the world in Estoril, Portugal from May 7-10, 2019.

 One of the largest respiratory health conferences worldwide, RDD Europe 2019 is a premium, interactive three-day conference offering a prestigious program that includes a plenary lecture and seven plenary sessions hosted by industry experts – including a U.S. FDA speaker – who will share their perspectives and latest accomplishments in pulmonary and nasal drug delivery. This international symposium also offers delegates the latest insights into issues facing the global inhalation community, and numerous business networking opportunities.

As part of their Diamond Sponsorship, Aptar Pharma will lead three interactive workshops dedicated to connected health.  Entitled “The Future of Connected Medicines: Promise and Potential Pitfalls”, these sessions will take place on Wednesday, May 8 and will be presented by Sai Shankar Director, Business Development – Connected Devices at Aptar Pharma along with David Van Sickle, Co-founder and CEO at Propeller Health.

Reaffirming their respiratory expertise, Aptar Pharma will also present two scientific posters during RDD Europe 2019, co-presented by Dr. Gerallt Williams, Director Scientific Affairs, Aptar Pharma:

  • “Human Factor studies for unit-dose nasal sprays – a case study”, co-presented by Williams, B. Grosjean, D. Chopard, P. Schwartz, J. Cabiddu
  • “Investigation of leachables from pMDIs containing HFA 152a”, co-presented by Sarrailh, A. Piquenot, O. Michelet, G. Williams.

In addition to co-organizing the conference, Aptar Pharma will showcase their extensive portfolio of MDIs, DPIs and BAIs, including the growing range of connected devices, at an interactive Exhibit Table. Available as either add-on or fully integrated, Aptar’s c-devices can deliver improved patient health outcomes through better adherence. Also, discover the portfolio of active packaging solutions from Aptar CSP Technologies, now part of the Aptar family, which can help optimize your drug product’s packaging environment.

As Platinum Sponsor, Aptar Pharma will be hosting the Gala Dinner at RDD Europe 2019, which will take place on Thursday May 9 at Sud Lisboa, located on the banks of the Tagus River in Lisbon. Gael Touya, President of Aptar Pharma, will be on hand to welcome guests to this much-anticipated event, which combines fine-cuisine, dancing and networking to cap off the conference.

Register today at https://www.rddonline.com/rddeurope2019  for RDD Europe 2019 – a must-attend conference for companies involved in research, development, testing and marketing of medicines, as well as devices and services associated with pulmonary or nasal products.

See full Press Release for details.

 

 

March 21, 2019

Aptar Pharma to Showcase New Market Innovations at Interphex 2019...

Aptar Pharma, a leading drug delivery systems provider, is pleased to be exhibiting at Interphex 2019, taking place April 2-4 at the Javits Center in New York City.

Located at Booth 1734, Aptar Pharma experts will be on hand to present our diverse portfolio of drug delivery systems, components, services and active packaging solutions, including our latest innovations across nasal, pulmonary, eye care, injectables and dermal drug delivery routes including our:

  • Bidose nasal drug delivery device, recently approved by the U.S. FDA for a breakthrough treatment of depression
  • Industry award-winning Aptar Pharma QuickStart™ Injectables – our Ready-to-Use drug development support package designed to accelerate time-to-market for research and development labs
  • Recently-launched PureHale – a portable and ready-to-use device designed to deliver natural care to upper airways
  • Expanded range of connected drug delivery devices, showing how Aptar Pharma is investing in the future of digital medicines
  • Active packaging solutions portfolio from Aptar CSP Technologies, now part of the Aptar family, which help optimize your drug product’s packaging environment.

Furthermore, Aptar Pharma will highlight our expanded state-of-the-art manufacturing facility in North America. Equipped with the latest technologies to meet growing quality requirements for regulated markets, find out how we have expanded our capabilities at our Congers, NY site to continue to deliver solutions to our customers’ drug delivery challenges.

Aptar Pharma’s PureHale will also be featured in a Technical Theater & Workshop session at Interphex 2019. Entitled “Portable care for your respiratory tract: Exploring new technology platforms”, this workshop will take place on April 3 at 4:00pm and will be presented by Aileen Power, Account Manager – Aptar Pharma Consumer Health Care division.

Interphex is a premier pharmaceutical, biotechnology and device development and manufacturing event, bringing over 11,000 global industry professionals and 650+ leading suppliers together to leverage quality, efficiency and cost effectiveness in today’s ever-changing global market.

To register to attend Interphex 2019, please click here.

March 21, 2019

Aptar Pharma’s Bidose Nasal Drug Delivery Device Approved by U....

Aptar Pharma, a leading drug delivery systems provider, is pleased to announce that its Bidose nasal spray device was recently approved by the U.S. FDA for a breakthrough therapy in the field of depression. This marks the first FDA approval and U.S. launch of a prescription drug using Aptar Pharma’s patented Bidose nasal spray delivery system.

This approval again demonstrates Aptar Pharma’s expertise in developing patient-friendly drug delivery solutions for breakthrough medicines. Aptar Pharma offers a broad portfolio of innovative technologies and a wide array of services to meet the highest quality standards of the pharmaceutical industry.

Designed for local or systemic delivery of drugs, Aptar Pharma’s Bidose liquid system is a robust, primeless, intuitive and easy-to-use device with 360° functionality and precise spray characteristics and provides accurate two-shot nasal drug delivery.

This customized Bidose liquid device is produced in Aptar Pharma’s state-of-the-art manufacturing facility in Congers, NY, which offers laboratory and other organizational capabilities to support nasal and injectable drug delivery systems.

This breakthrough therapy approval is an example of a Combination Product, and benefited from Aptar Pharma’s Services offering, a comprehensive portfolio of stage-specific packages designed to proactively address regulatory needs to accelerate approval.

“We are pleased that Aptar Pharma’s Bidose nasal delivery device has been approved by the FDA for this breakthrough therapy in the field of depression,” explained Gael Touya, President, Aptar Pharma. “This project marks close to a 10-year customer collaboration and once again demonstrates Aptar Pharma’s ability to develop and launch complex drug delivery systems worldwide.”

For more details, please download for our full Press Release.

March 18, 2019

Aptar Pharma to Exhibit Latest Injectable Developments at 2019 PD...

Aptar Pharma is pleased to be exhibiting at the 2019 PDA Annual Meeting, which takes place March 11-13, 2019 at the Marriott Marquis San Diego, CA.

This year at Aptar Pharma’s Booth No. 600, our experts will be showcasing the latest developments in our Premium product portfolio for elastomers, including Aptar Pharma’s PremiumCoat™.

Another highlight of our booth will be our industry award-winning Aptar Pharma QuickStart™ for Injectables solution – a sterile, Ready-To-Use (RTU) drug development offering designed specifically to accelerate the development time for start-ups and early stage development, R&D, biotechs and university research organizations. Recently launched, Aptar Pharma QuickStart™ for Injectables is available for online ordering here.

Visitors to our booth can also find out more about Aptar Pharma’s expanded manufacturing capacity in North America.

During 2019 PDA Annual Meeting, Aptar Pharma will present two posters at the Poster Sessions:

Migration Study to Evaluate the Impact of Steam vs. Gamma Irradiation in Ready-To-Use (RTU) Uncoated Stoppers and Fluorinated (ETFE) Film Coated Stoppers” will be presented by Michael J. Mayer, Senior Scientist from Next Breath, a specialty company of Aptar Pharma.

Establishing a Market Leading Answer to a Reduced Particulates Profile for Elastomeric Solution” will be presented by Arnaud Fournier, Senior Business Project Manager, Aptar Pharma.

Delegates at the event will have the opportunity to attend the Poster Sessions on both Tuesday, March 12 and Wednesday, March 13 between 10:00am and 10:45am.

With this year’s theme Solving Manufacturing and Supply Challenges for Current and Future Medicinal Products, the 2019 PDA Annual Meeting is the PDA’s flagship annual event, providing a learning and sharing venue for industry experts to gather the latest and most comprehensive information in the pharmaceutical manufacturing field.

Aptar Pharma is once again thrilled to be part of this event. To connect with Aptar Pharma and meet our team of experts, be sure to drop by our Booth No. 600. Register for the 2019 PDA Annual Meeting here.

March 6, 2019

Aptar Pharma’s Preservative-Free Multidose Dispenser Approved A...

Aptar Pharma is pleased to announce that its innovative, preservative-free multidose Ophthalmic Squeeze Dispenser has been approved for Santen’s prescription drug Taflotan®/Saflutan® for the reduction of elevated intraocular pressure (IOP) in open angle glaucoma and ocular hypertension in 26 countries in Europe.

This approval reconfirms the market-leading position of Aptar Pharma’s Ophthalmic Squeeze Dispenser as an approved delivery system for eye disease treatment formulations without any preservatives.

Aptar Pharma is working closely with leading global ophthalmology specialist Santen Pharmaceutical Co., Ltd. to improve patient safety, achieve dosing accuracy and maintain product integrity.

A specialized global pharmaceutical company dedicated to the ophthalmology field, Santen is dedicated to the development and marketing of preservative-free drugs as part of its mission to contribute to the well-being of their patients, as well as society.

“We are delighted to launch preservative-free multi-dose formulations of these glaucoma therapies in Europe,” said Luis Iglesias, Corporate Officer and Head of EMEA, Santen. “By providing highly effective and well-tolerated, preservative-free medicines, with the option for multi-dose bottles, we hope to empower patients in their daily lives and improve the management of their condition.”

Aptar Pharma’s Ophthalmic Squeeze Dispenser system is the result of more than 10 years of development and experience in the delivery of preservative-free ophthalmic solutions. Patients and consumers in the U.S., Europe, Latin America and Asia have benefited from this technology since 2012, with more than 175 commercial references now available on the market (1).

“The proven and unrivalled microbiological safety, combined with a precise and reproducible drop ejection, allows pharmaceutical customers worldwide to enter into discussions with regulatory agencies such as the German BfArM with confidence,” said Matthias Birkhoff, VP Business Development, Aptar Pharma. Mr. Birkhoff also referred to the user-friendliness of the system, adding “The ergonomic, pocket-size design and the intuitiveness of a squeezable container with a low actuation force certainly contribute to the high levels of acceptance among patients and consumers worldwide.”

Please click here to download the full Press Release.

(1) Reference: Aptar Pharma White Paper available here.

 

February 26, 2019

Aptar Pharma QuickStart™ Injectables, a Drug Development Soluti...

Aptar Pharma is pleased to announce that their recently-launched QuickStart™ for Injectables has won Best Innovation in Packaging Material & Component category at the 2019 Pharmapack Awards in Paris, France.

QuickStart™ Injectables, which was showcased at the Innovation Gallery at Pharmapack this year, is a sterile, Ready-To-Use (RTU) drug development offering designed specifically to accelerate the development time for start-ups and early stage development, R&D, biotechs and university research organizations.

Launched at CPhI Worldwide in Madrid in October 2018, this highly-innovative injectable development package comes with gamma-sterilized stoppers and push-off caps from Aptar Pharma and EMA Pharmaceuticals respectively, and ETO sterilized vials from Schott, providing a one-stop solution allowing developers to focus on their science and chemistry.

QuickStart™ Injectables offers everything needed for the small-volume filling of high value formulations, including various sizes and configurations of vials, stoppers and caps, giving customers better quality, flexibility, convenience and speed. It also includes all of the quality and technical documentation required to verify the sterilization and compatibility (CCI) of components to proactively address regulators’ needs and accelerate approval.

Aptar Pharma also announced at Pharmapack 2019 that the award-winning QuickStart™ development package is now available for online purchase via the Aptar Pharma website utilizing a convenient, easy-to-use configurator, further simplifying access for research scientists and drug developers with a click of a button.

Accepting the award at Pharmapack 2019, Bas Van Buijtenen, President of the Aptar Pharma Injectables Division said, “We are delighted that QuickStart™ Injectables has won ‘Best Innovation in Packaging Material & Component’ at this year’s Pharmapack Awards. With QuickStart™ Injectables, we are enabling small scale sterile fills for innovative drug companies. Because we offer a small scale packaging solution identical to what will be used for large scale fills, these innovators gain reliability and time in their drug development pipeline”.

For more details and further information on QuickStart™ Injectables, please click here for the full Press Release.

February 7, 2019

Aptar Pharma to Exhibit Latest Innovations at Pharmapack 2019, Pa...

Aptar Pharma will be a key exhibitor once again at Pharmapack 2019, which will take place February 6-8 at Paris Expo, Porte de Versailles, in Paris, France. Located at booth B42, Hall 7.2, Aptar Pharma will present their diverse portfolio of drug delivery systems, components and active packaging solutions, as well as their latest innovations across nasal, pulmonary, eye care, injectables and dermal drug delivery routes, including:

  • PureHale – their recently launched, portable and ready-to-use device designed to deliver natural care to upper airways
  • Their expanded range of connected drug delivery devices designed to help increase dose adherence and improve patient health outcomes
  • Aptar Pharma Services, a portfolio of stage-specific development packages to help customers accelerate their development journey from molecule to market
  • Active packaging solutions from Aptar CSP Technologies, now part of the Aptar family. Aptar CSP Technologies offers a variety of innovative active packaging solutions to help optimize your drug product’s packaging environment

Pharmapack provides invaluable insight into and recognition of the latest trends, developments and regulatory changes impacting the industry, as well as a wide variety of learning opportunities.

As part of the Innovation Gallery at Pharmapack this year, Aptar Pharma will showcase two of their newest product launches, PureHale and QuickStart™ Injectables – their Ready-to-Use drug development support packages designed to accelerate time-to-market for research and development labs. Both innovations are contenders for the Pharmapack 2019 Awards, which will be announced during the show.

Three of Aptar Pharma’s experts will share their specialist knowledge during Pharmapack’s Learning Lab sessions on Wednesday, February 6:

  • Drug Repurposing – Broadening Patient Accessibility via a Change in Drug Delivery System will be presented by Dr. Gerallt Williams, Director – Scientific Affairs at Aptar Pharma.
  • Building a Successful Eco-System for Digital Medicines will be presented by Sai Shankar, Director Business Development – Connected Devices
  • Debunking the Leachable Myths of Gamma Sterilization: A Migration Study of Steam versus Gamma will be presented by Dr. Julie D. Suman, President and Founder of Next Breath, an Aptar Pharma Business.

Visit Aptar Pharma at Booth B42, Hall 7.2, where their team of experts will be on hand to demonstrate their technologies and discuss ways they can partner with customers to ensure their drug delivery challenges are met.

We look forward to welcoming you at Pharmapack 2019!

Read full Press Release here.

 

 

December 20, 2018

Aptar Pharma to Highlight its Latest Innovations at CPhI India 20...

Aptar Pharma is pleased to be exhibiting once again at CPhI India 2018.

After more than a decade of success in Mumbai, this year’s CPhI India will take place from December 12 to 14, 2018 at the India Expo Centre, Greater Noida, Delhi NCR.

Visitors to the Aptar Pharma Booth 14C29 in Hall 14 will be greeted by our team of experts who will showcase Aptar Pharma’s wide drug delivery devices product portfolio.

Aptar Pharma is excited to present its expanded range of connected devices at the event. These intuitive devices feature fully-connected functionality and software integration, which can improve patient health outcomes through improved adherence.

Another major highlight of Aptar Pharma’s presence at this year’s CPhI India will be our recently launched PureHale – an industry-first, a portable and ready-to-use nebulizer-like device designed to deliver natural care to upper airways.

CPhI India, which takes place alongside India Pharma Week, is predicted to attract more than 50,000 visitors from 122 countries, along with almost 1500 exhibitors, providing an excellent opportunity to network with fellow pharmaceutical experts and learn about the latest developments in India’s pharmaceutical industry.

Aptar Pharma looks forward to welcoming you there!

December 6, 2018

Aptar Pharma to Showcase Latest Connected Health Innovations and ...

Aptar Pharma will exhibit its broad respiratory portfolio as well as its new range of active packaging technologies for respiratory devices at the annual Drug Delivery to the Lung (DDL) Conference 2018.

DDL 2018, which takes place from December 12-14 in Edinburgh, Scotland, is a renowned conference for scientists, academics, clinicians, regulatory and industry specialists involved in the development of inhalation medicines.

Aptar Pharma is a worldwide leader in respiratory drug delivery devices for the treatment of asthma and COPD, and a Platinum sponsor of DDL 2018. At their booth #244, Aptar Pharma’s team of experts will showcase their innovative and extensive range of respiratory drug delivery systems and demonstrate how Aptar Pharma can help accelerate speed-to-market.

Aptar Pharma’s exhibition stand will also highlight their expanded range of connected devices. These intuitive devices feature fully-connected functionality and software integration, which can improve patient health outcomes through improved adherence.

Also featured with Aptar Pharma will be Aptar CSP Technologies, now part of AptarGroup, Inc.

Aptar CSP Technologies offers a variety of innovative active packaging solutions for respiratory that protect products to control moisture, extend shelf life and improve their performance.

Click here to download our full Press Release.

November 28, 2018

Aptar Pharma Co-Organizes the Third Edition of RDD Asia® in Kera...

Aptar Pharma is pleased to announce the co-organization and its diamond sponsorship of the third Respiratory Drug Delivery (RDD®) Asia scientific conference, which will take place at the Grand Hyatt Kochi hotel from November 14-16 in Kerala, India.

In addition to co-organizing the conference and exhibiting, Aptar Pharma will host an interactive workshop on Thursday, November 15 addressing the most recent FDA guidance on Combination Products, with a focus on respiratory and nasal drug products. The seminar, entitled “Decoding FDA’s Recent Combination Drug Product Guidance: Applications to DPIs, pMDIs, and Nasal Sprays,” will be presented by Badre Hammond, Associate Director, Market Development at Aptar Pharma. This workshop, which will be repeated three times during the day, will give insights into optimal approaches to help secure approval in this changing and challenging regulatory landscape. It will review various topics, including the definition of combination products, NDA/ANDA submissions, regulatory pathway review, Human Factor studies in the context of combination products, and clarify expectations on the sponsor, the device supplier and regulators.

Furthermore, Dr. Gerallt Williams, Director of Scientific Affairs at Aptar Pharma, will present a poster entitled “Interpretation Of Manual Actuation Profiles From Nasal Bi-dose Spray Devices”, which demonstrates their impact on analytical and regulatory requirements.

Building on the successes of previous RDD conferences in the U.S., Europe and Asia, RDD Asia 2018 is recognized as one of the premium international meetings in the area. More than 200 delegates from Asia and beyond are expected to attend.

To connect with Aptar Pharma at RDD Asia 2018 and meet their team of experts, register at:

https://www.rddonline.com/rdd/rdd.php?id=16

Click here to download our full Press Release.

 

November 5, 2018

Aptar Pharma QuickStart™, an injectable device development kit,...

Aptar Pharma, a leading provider of innovative drug delivery systems, in combination with Schott Glass and EMA Pharmaceuticals, has announced that it will launch Aptar Pharma QuickStart™ for injectable drug development at CPhI Worldwide 2018, in Madrid, Spain, October 9th.

Aptar Pharma QuickStart™ is a sterile, Ready-To-Use (RTU) drug development support kit designed specifically for research & development labs. A package complete with glass vials, elastomeric stoppers and caps, QuickStart™ provides everything needed for the small volume filling of high value formulations. Also included in the kit are all the quality and technical documentation required to verify the sterilization and compatibility (CCI) of components. Co-developed alongside Schott and EMA Pharmaceuticals, Aptar Pharma QuickStart™ is available to cater to different sizes and configurations of vials, stoppers and caps.

Aptar Pharma’s proven expertise in device development and formulation helps ensure that QuickStart™’s components satisfy all regulatory requirements, allowing users to access commercial scale quality at a development stage cost.

CPhI Worldwide, which takes place October 9-11, 2018 at IFEMA, Feria de Madrid, will welcome more than 45,000 pharma professionals, which provides a prime opportunity to demonstrate the value of Aptar Pharma QuickStart™ to prospective partners.

To read full Press Release, click here.

October 9, 2018

Aptar Pharma Launches PureHale, a New Portable and Ready-to-Use U...

Aptar Pharma continues its commitment to meeting new market trends with the release of an industry first, PureHale, a new portable and ready-to-use delivery solution designed for upper respiratory care. PureHale is a revolutionary and intuitive device which – when used in combination with saline or other natural ingredient formulations – helps relieve the symptoms of upper respiratory system conditions.

With the ongoing rise in pollution, which is a major environmental risk to health, the need for upper respiratory relief is more prominent than ever. Utilizing Aptar Pharma’s well-established Bag-on-Valve system, PureHale’s innovative technology distributes a continuous fine mist (20-30µm) that gently cleanses, moisturizes and soothes the upper respiratory tract. When used in combination with a customer’s formulation, it could help to reduce irritations caused by coughs, colds, allergies, respiratory problems and dry nose/throat issues.

PureHale’s portability allows consumers to relieve their symptoms wherever and whenever needed. Unlike traditional nebulizers, the PureHale system does not require batteries or the prefilling of a reservoir and does not need to be plugged in or charged. The PureHale technology platform is quieter and lighter than traditional nebulizers, is easy-to-use and includes mask and mouthpiece options, offering adaptable treatment and suitable for family use.

Guenter Nadler, Director Business Development at Aptar Pharma said of this latest launch, “We are really excited to announce this newest Aptar Pharma innovation. We have seen a real need for a device of this kind – traditional nebulizers come with a set of challenges including complexities in setup, manual dexterity requirements and overall usage time. Meanwhile, challenges during medication administration include poor inhalation technique, duration of nebulization and understanding how to achieve optimal efficacy. PureHale has been designed specifically with these challenges in mind and offers a solution by simplifying the entire process.”

PureHale will be officially launched at CPhI Worldwide in Madrid on October 9th at Booth 4D10 and is a finalist in the CPhI Pharma Awards in the Excellence in Pharma: Drug Delivery Device category.

Click here for full the Press Release.

 

October 2, 2018

Aptar Pharma to Showcase Our Latest Offerings at PDA PFS, Orlando...

Aptar Pharma is pleased to be exhibiting at 2018 PDA Universe of Pre-Filled Syringes and Injection Devices (PDA PFS), taking place October 8-9, 2018 in Orlando, Florida.

At our Booth No. 601 we will be showcasing the latest developments in our Premium offering and PFS product portfolio.

Our expert team will be presenting the following posters at PDA PFS entitled:

“Migration Study to Evaluate the Impact of Steam vs. Gamma Irradiation in Ready-To-Use (RTU) Uncoated Stoppers and Fluorinated (ETFE) Film Coated Stoppers” presented by Michael J. Mayer, Senior Scientist from Next Breath, a specialty company of Aptar Pharma.

“Establishing a Market Leading Answer to a Reduced Particulates Profile for Elastomeric Solution” presented by Arnaud Fournier, Senior Business Project Manager, Aptar Pharma.

Aptar Pharma will also moderate a session during PDA PFS. Taking place on Monday, October 8 from 1.30 p.m. to 3 p.m., the session entitled ‘B1: When Packaging Becomes More than Packaging’, will be moderated by Joel Cotten, Business Development Director, Aptar Pharma, and will discuss, from a high-level perspective, how packaging must protect injectable drugs as well as the intermediate injection systems until they reach the final users. Some of the most recent innovations in the market that could change the future of the injectable packaging offering will also be discussed.

For more details on this session, please click here.

September 25, 2018

Aptar Pharma to launch PureHale and showcase its portfolio of con...

Aptar Pharma, a leading drug delivery systems provider, is pleased to showcase its commitment to meeting new market trends at CPhI Worldwide this year. The world’s largest pharma trade show, held 9 – 11 October in Madrid, will see more than 100,000 pharmaceutical professionals coming together for exhibitions, conferences and online communities, and this year Aptar Pharma will be showcasing an industry first with its PureHale device – a new portable drug delivery device designed for upper respiratory care – at stand 4D10.

In addition to PureHale, AptarPharma will also reveal:

  • A range of new connected drug delivery devices designed to help increase dose adherence and improve patient health outcomes
  • A portfolio of gamma-sterilized drug delivery components to reduce bioburden
  • Aptar Pharma’s Support Services initiative, a portfolio of stage-specific development packages to help customers in their journey from molecule to market

Along with showcasing its range of innovative drug delivery devices that address nasal, pulmonary, eye care, injectables and dermal drug delivery routes at Aptar Pharma’s exhibit stand, the company will also be sharing various new solutions in prescription and over-the-counter treatments.

Furthermore, Aptar Pharma executives will be delivering three Pharma Insight Briefings outlining the latest trends, technology and product innovations:

“Debunking the leachable myths of gamma sterilization: A migration study of steam vs gamma” – Julie D. Suman, R.Ph., Ph.D., President of Next Breath, a division of Aptar Pharma. Tuesday, 9 October, 11:50-12:20.

“Portable care for your respiratory tract: Exploring new technology platforms” – Guenter Nadler, Director Business Development, Aptar Pharma. Tuesday, 9 October, 12:30-13:00.

“Building a connected devices eco-system for digital medicines” – Sai Shankar, Director Business Development, Aptar Pharma. Wednesday, 10 October, 13:50-14:20.

Aptar Pharma’s team of experts will be on hand at our booth 4D10 to explain and demonstrate their latest drug delivery technologies and to discuss ways they can partner with customers to ensure their drug delivery challenges are met.

For more information about Aptar Pharma’s presence at CPhI Worldwide 2018, please click here to view the full press release.

September 17, 2018